THE RELATIONSHIP BONE MINERAL DENSITY AND HIGH-DOSE SHORT-TERM CORTICOSTEROID THERAPY IN MULTIPLE SCLEROSIS PATIENTS
Introduction: Previous studies were reported that osteoporosis and bone fracture occurs more frequently among Multiple sclerosis patients than the general population. The aim of this study to investigate the affects of total doses of short-term, high dose corticosteroids on bone mineral density and other affecting factors for bone mineral density in Relapsing-remitting type Multiple Sclerosis patients.
Material and methods: Fifty-four patients (37 females, 17 males) with relapsing-remitting type Multiple Sclerosis who filled the diagnostic criteria according to McDonald criteria were included in the study. Femoral and lumbar bone mineral density were measured using dual energy X-ray absorptiometry. Expanded Disability Status Scale, disease duration, number of attacks, cumulative corticosteroid dose were recorded. Serum calcium, potassium, phosphorus, vitamin D, parathormone and osteocalcin levels were measured. Patients were divided into two groups: patients who have received at least 20 g intravenous metilprednisolone (Group I) and patients who have received less than 20 g intravenous metilprednisolone (Group II). We analysed association between cumulative corticosteroid dose and each parameters.
Results: Osteopenia was present in 46.2% and osteoporosis in 5.5% of the study population according to femoral neck bone mineral density. Femoral bone mineral density was significantly lower among patients. There was no correlation between cumulative dose of corticosteroid and bone mineral density.
Conclusion: Low bone mineral density and osteoporosis are common in Multiple sclerosis patients. High-dose steroid therapy is not be the primary cause of osteoporosis in patients with multiple sclerosis.
Bazelier MT, vanStaa T, Uitdehaag BMJ, Cooper C, Leufkens HGM, Vestergaard P, et al. The risk of fracture in patients with multiple sclerosis: The UK general practice research database. JBMR. 2011;26(9):2271-9.
Bhattacharya RK, Vaishnav N, Dubinsky RM. Is there an increased risk of thehipfracture in multiples clerosis? Analysis of the Nationwide in patient sample. J Multidiscip Health. 2014;7:119-22.
Dobson R, Ramagopalan S, Giovannoni G. Bone health and multiple sclerosis. Mult Scler. 2012;18(11):1522-8.
Dong G, Zhang N, Wu Z, Liu Y, Wang L. Multiple sclerosis increases fracture risk: A meta-analysis. Biomed Res Int. 2015; 2015: 650138.doi: 10.1155/2015/650138.
Gibson JC, Summers GD. Bone health in multiple sclerosis. Osteoporosis Int. 2011;22(12):2935-49.
Van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13(10):777-87.
Smets I, VanDeun L, Bohyn C, vanPesch V, Vanopdenbosch L, Dive D, et al. Corticosteroids in the management of acute multiple sclerosis exacerbations. Acta Neurol Belg. 2017; 117(3):623–33.
Sandhu SK, Hampson G. The pathogenesis, diagnosis, investigation and management of osteoporosis. J Clin Pathol. 2011;64(12):1042-50.
Ayatollahi A, Mohajeri-Tehrani MR, Nafissi S. Factors affecting bone mineral density in multiple sclerosis patients. Ir J Neurol. 2013;12(1):19-22.
Krela-Kazmierczak I, Michalak M, Szymczak-Tomczak A, Łykowska-Szuber L, Stawczyk-Eder K, Waszak K et al. Prevalence of osteoporosis and osteopenia in a population of patients with inflammatory bowel diseases from the Wielkopolska Region. Pol Arch Intern Med. 2018;128(7-8):447-54.
Kepczynska K, Zajda M, Lewandowski Z, Przedlacki J, Zakrzewska-Pniewska B. Bone metabolismand vitamin D status in patients with multiple sclerosis. Neurol Neurochir Pol. 2016;50(4):251-7.
Kirbas A, Kirbas S, Anlar O, Turkyilmaz AK, Cure MC, Efe H. Investigation of the relationship between vitamin D and bone mineral density in newly diagnosed multiples clerosis. Acta Neurol Belg. 2013;113(1):43-7.
Olsson A, Oturai DB, Sorensen PS, Oturai PS, Oturai AB. Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis. Mult Scler. 2015;21(12):1557-65.
Tyblova M, Kalincik T, Zikan V, Havrdova E. Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis. Eur J Neurol. 2015;22(4):624–32.
Weinstock-Guttman B, Gallagher E, Baier M, Green L, Feichter J, Patrick K, et al. Risk of bone loss in men with multiple sclerosis. Mult Scler. 2004;10(2);170-5.
Zengin Karahan S, Boz C, Kilic S, Can Usta N, Ozmenoglu M, Altunayoglu Cakmak V, et al. Lack of association between pulse steroid therapy and bone mineral density in patients with multiple sclerosis. Mult Scler Int. 2016;2016:5794910. doi: 10.1155/2016/5794910.
Zikan V, Tyblova M, Raska JR I, Havrdova E, Luchavova M, Michalska D, et al. Bone mineral density and body composition in men with multiple sclerosis chronically treated with low dose glucocorticoids. Physiol Res. 2012;61(4):405-17.
Zorzon M, Zivadinov R. Locatelli L, Giuntini D, Toncic M, Bosco A, et al. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol. 2005;12(7):550-6.
Clelant BT, Papanek P, Ingraham BA, Harkins A, Garnier-Villarreal M, Woo D, et al. Determinants of low bone mineral density in people with multiple sclerosis: Role of physical activity. Mult Scler Relat Disord. 2020;38:101864.doi: 10.1016/j.msard.2019.101864.
Huang Z, Qi Y, Du S, Chen G, Yan W. BMI levels with MS bone mineral density levels in adults with multiple sclerosis: a meta-analysis. Int J Neurosci. 2015;125(12):904-12.
Triantafyllou N, Lambrinoudaki I, Thoda P, Andreadou E, Kararizou E, Alexandrou A, et al. Lack of association between vitamin D levelsand bone mineral density in patients with multiple sclerosis. J Neur Sci. 2012;313 (1-2):137-41.
Terzi T, Terzi M, Tander B, Cantürk F, Onar M. Changes in bone mineral densityand bone metabolism markers in premenopausal women with multiple sclerosis and the relationship to clinical variables. J Clin Neurosc. 2010;17(10):1260-4.
Coskun Benlidayi I, Basaran S, Evlice A, Erdem M, Demirkiran M. Prevalence and risk factors of low bone mineral density in patients with multiple sclerosis. Acta Clin Belg. 2015;70(3):188-92.
Tuzun S, Altintas A, Karacan I, Tangurek S, Saip S, Siva A. Bone status in multiple sclerosis: beyond corticosteroid. Mult Scler. 2003;9(6):600-4.
Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain. 2009;132(Pt5):1146-60.
Ozgocmen S, Bulut S, Ilhan N, Gulkesen A, Ardicoglu O, Ozkan Y. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab. 2005;23(4):309-13.
Wei J, Karsenty G. An overview of the metabolic functions of osteocalcin. Rev Endoc Metab Disord. 2015;16(2):93-8.
Weinstock-Guttman B, Hong J, Santos R, Tamano-Blanco M, Badgett D, Patrick K, et al. Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. Mult Scler. 2006;12(5):541-50.
Agrawal BK, Jain V, Varshney A. Bone turn over markers in women can predict low bone mineral density. Int J Res Med Sci. 2015;3(4):876-9.
Susanto LTM. Serum osteocalcin and bone mineral density in postmenopausal women. Univ Med. 2011;30(3):155-61.
- There are currently no refbacks.
Copyright (c) 2020 Pinar Bekdik Sirinocak, Neslihan Eskut, Ufuk Sener, Yasar Zorlu
This work is licensed under a Creative Commons Attribution 4.0 International License.